

## EA6134 (DREAMseq) Clinical Trial Results Summary

### Testing the Therapy Sequence for Advanced BRAF Mutation Melanoma

#### What did this trial involve and who was it for?

The EA6134/DREAMseq trial was for patients with advanced melanoma, those with stage III or IV melanoma that could not be removed with surgery (unresectable), whose tumors had a mutation in the *BRAF* gene. *BRAF* mutations drive cancer growth and are present in roughly half of all melanomas. The trial was testing if patients have better results when they start treatment with targeted therapy drugs (dabrafenib and trametinib) followed by immunotherapy drugs (nivolumab and ipilimumab)—versus starting with immunotherapy drugs followed by targeted drugs. A total of 300 patients participated in EA6134/DREAMseq.

#### What are the results?

Results showed that patients did better with a treatment sequence that began with the immunotherapy drugs and was followed, if needed, by the targeted therapy drugs. Researchers found a 20% increase in two-year survival in the group that received immunotherapy first, compared with the group that received targeted therapy first.

#### What do the results mean for patients?

These results are practice-changing. They establish immunotherapy—followed by targeted therapy if needed—as the preferred treatment approach for the vast majority of patients with advanced melanoma that has a *BRAF* gene mutation.

---

#### For more information, go to:

- United States National Institutes of Health (NIH) Library of Medicine:  
<https://www.clinicaltrials.gov/study/NCT02224781>
  - ECOG-ACRIN Website:  
<https://ecog-acrin.org/practice-changing-trial-results-for-advanced-skin-cancer/>
  - *Journal of Clinical Oncology*:  
<https://ascopubs.org/doi/full/10.1200/JCO.22.01763>
- 

#### About ECOG-ACRIN

This trial was led by the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN). ECOG-ACRIN is a membership-based scientific organization that designs and conducts cancer research involving adults who have or are at risk of developing cancer. ECOG-ACRIN is a component of the National Cancer Institute's National Clinical Trials Network. Learn more at [www.ecog-acrin.org](http://www.ecog-acrin.org).

*To all the patients that participated in this trial, thank you. Without the involvement of patients like you, this research would not have been completed.*